TY - JOUR
T1 - Typical and atypical pathology in primary progressive aphasia variants
AU - Spinelli, Edoardo G.
AU - Mandelli, Maria Luisa
AU - Miller, Zachary A.
AU - Santos-Santos, Miguel A.
AU - Wilson, Stephen M.
AU - Agosta, Federica
AU - Grinberg, Lea T.
AU - Huang, Eric J.
AU - Trojanowski, John Q.
AU - Meyer, Marita
AU - Henry, Maya L.
AU - Comi, Giancarlo
AU - Rabinovici, Gil
AU - Rosen, Howard J.
AU - Filippi, Massimo
AU - Miller, Bruce L.
AU - Seeley, William W.
AU - Gorno-Tempini, Maria Luisa
N1 - Funding Information:
This study was supported by the NIH National Institute of Neurological Disorders and Stroke (R01 NS050915), NIH National Institute on Deafness and Other Communication Disorders (K24 DC015544), NIH National Institute on Aging (P50 AG03006, P50 AG023501, P01 AG019724), State of California (DHS04-35516), Alzheimer's Disease Center of California (03-75271 DHS/ADP/ARCC), Larry L. Hillblom Foundation, John Douglas French Alzheimer's Foundation, Koret Family Foundation, Consortium for Frontotemporal Dementia Research, and McBean Family Foundation. We thank the patients and their families for the time and effort they dedicated to the research; Drs I. Mackenzie and W. Ellis for assistance with 2 of the autopsies; Drs P. Pressman and C. Watson for their help in reviewing a draft manuscript and tables; and Dr G. Coppola for assistance with genetic data.
Publisher Copyright:
© 2017 American Neurological Association
PY - 2017/3/1
Y1 - 2017/3/1
N2 - Objective: To characterize in vivo signatures of pathological diagnosis in a large cohort of patients with primary progressive aphasia (PPA) variants defined by current diagnostic classification. Methods: Extensive clinical, cognitive, neuroimaging, and neuropathological data were collected from 69 patients with sporadic PPA, divided into 29 semantic (svPPA), 25 nonfluent (nfvPPA), 11 logopenic (lvPPA), and 4 mixed PPA. Patterns of gray matter (GM) and white matter (WM) atrophy at presentation were assessed and tested as predictors of pathological diagnosis using support vector machine (SVM) algorithms. Results: A clinical diagnosis of PPA was associated with frontotemporal lobar degeneration (FTLD) with transactive response DNA-binding protein (TDP) inclusions in 40.5%, FTLD-tau in 40.5%, and Alzheimer disease (AD) pathology in 19% of cases. Each variant was associated with 1 typical pathology; 24 of 29 (83%) svPPA showed FTLD-TDP type C, 22 of 25 (88%) nfvPPA showed FTLD-tau, and all 11 lvPPA had AD. Within FTLD-tau, 4R-tau pathology was commonly associated with nfvPPA, whereas Pick disease was observed in a minority of subjects across all variants except for lvPPA. Compared with pathologically typical cases, svPPA-tau showed significant extrapyramidal signs, greater executive impairment, and severe striatal and frontal GM and WM atrophy. nfvPPA-TDP patients lacked general motor symptoms or significant WM atrophy. Combining GM and WM volumes, SVM analysis showed 92.7% accuracy to distinguish FTLD-tau and FTLD-TDP pathologies across variants. Interpretation: Each PPA clinical variant is associated with a typical and most frequent cognitive, neuroimaging, and neuropathological profile. Specific clinical and early anatomical features may suggest rare and atypical pathological diagnosis in vivo. Ann Neurol 2017;81:430–443.
AB - Objective: To characterize in vivo signatures of pathological diagnosis in a large cohort of patients with primary progressive aphasia (PPA) variants defined by current diagnostic classification. Methods: Extensive clinical, cognitive, neuroimaging, and neuropathological data were collected from 69 patients with sporadic PPA, divided into 29 semantic (svPPA), 25 nonfluent (nfvPPA), 11 logopenic (lvPPA), and 4 mixed PPA. Patterns of gray matter (GM) and white matter (WM) atrophy at presentation were assessed and tested as predictors of pathological diagnosis using support vector machine (SVM) algorithms. Results: A clinical diagnosis of PPA was associated with frontotemporal lobar degeneration (FTLD) with transactive response DNA-binding protein (TDP) inclusions in 40.5%, FTLD-tau in 40.5%, and Alzheimer disease (AD) pathology in 19% of cases. Each variant was associated with 1 typical pathology; 24 of 29 (83%) svPPA showed FTLD-TDP type C, 22 of 25 (88%) nfvPPA showed FTLD-tau, and all 11 lvPPA had AD. Within FTLD-tau, 4R-tau pathology was commonly associated with nfvPPA, whereas Pick disease was observed in a minority of subjects across all variants except for lvPPA. Compared with pathologically typical cases, svPPA-tau showed significant extrapyramidal signs, greater executive impairment, and severe striatal and frontal GM and WM atrophy. nfvPPA-TDP patients lacked general motor symptoms or significant WM atrophy. Combining GM and WM volumes, SVM analysis showed 92.7% accuracy to distinguish FTLD-tau and FTLD-TDP pathologies across variants. Interpretation: Each PPA clinical variant is associated with a typical and most frequent cognitive, neuroimaging, and neuropathological profile. Specific clinical and early anatomical features may suggest rare and atypical pathological diagnosis in vivo. Ann Neurol 2017;81:430–443.
UR - http://www.scopus.com/inward/record.url?scp=85015714544&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85015714544&partnerID=8YFLogxK
U2 - 10.1002/ana.24885
DO - 10.1002/ana.24885
M3 - Article
C2 - 28133816
AN - SCOPUS:85015714544
SN - 0364-5134
VL - 81
SP - 430
EP - 443
JO - Annals of Neurology
JF - Annals of Neurology
IS - 3
ER -